Sterling Capital Management LLC
Position in GYRE — Gyre Therapeutics, Inc.
CIK 1329883
CHARLOTTE, NC
Position in GYRE
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$1,060
+$649 QoQ
Shares Held
161
+172.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#45
of 60 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sterling Capital Management LLC holds $37,355,316 across 285 Biotechnology names. GYRE ranks #259 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,014 | $6,244,129 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
8,648 | $4,295,721 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
17,337 | $4,177,696 | |
| 4 | RPRX |
Royalty Pharma plc
|
66,034 | $3,702,526 | |
| 5 | ASND |
Ascendis Pharma A/S
|
13,727 | $3,661,265 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,687 | $1,711,957 | |
| 7 | VCEL |
Vericel Corp
|
31,489 | $1,400,945 | |
| 8 | INSM |
INSMED Inc
|
12,580 | $1,341,279 |
All Filings in GYRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,060 | 161 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $411 | 59 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $416 | 59 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $164 | 22 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $242 | 33 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $818 | 106 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $2,613 | 216 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $263 | 21 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||